Vivos Inc Signs a MOU for a New Regional Clinic in NY for IsoPet Therapy

Rhea-AI Summary

Vivos Inc. (OTCQB: RDGL) has signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East Meadow, New York, to establish an IsoPet regional therapy center. This center will focus on treating cancerous tumor margins post-surgery, potentially extending pet lives. Following the acquisition of a radioactive material handling license and necessary training, the center aims to expand its capabilities to treat other solid tumors. The initiative is backed by the Veterinary Medicine Advisory Board, led by Dr. Mike Korenko.

Positive

• Establishment of a regional therapy center in a major population area.
• Focus on treating cancerous tumors, which could significantly enhance revenue opportunities.
• Support from the Veterinary Medicine Advisory Board underscores credibility and expert backing.

Negative

• Reliance on obtaining the radioactive material handling license and successful certification training.
• Potential delays in operational launch may impact anticipated revenue generation.

Richland WA, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it signed a Memorandum of Understanding with the Animal Hospital Surgical Center in East Meadow New York on Long Island to become an IsoPet regional therapy center. Vivos Inc is currently working on obtaining the radioactive material handling license and on completing their certification training. They will be specializing in treating the margin of cancerous tumors after they have been surgically removed. This is expected to provide additional life extension. This application was recommended by our Veterinary Medicine Advisory Board.

Dr. Mike Korenko stated, “After licensing and certification, this will be our first east coast regional center and it is near a major population center. Initially it will be specializing in treating the margins of resected tumors, but they will have the capability to treat other solid tumors. As thought leaders and experienced surgeons Dr. Tomas Infernuso and Dr. Joe Impellizeri are also interested in applying their non-intrusive surgical techniques to treat a range of internal tumors within the pets, such a brain and bladder cancers. We expect to learn from their experience and transfer that knowledge to other clinics.”

About Vivos Inc. (OTCQB: RDGL)

Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet^®) and in humans (Radiogel^™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

Radiogel^™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

Radiogel^™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.

The Isopet^® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.

In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that Isopet^® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval was required for treating skin cancer, which is the largest market sector. Following the demonstration phase, Vivos is able to generate revenue through the sale of Isopet^® to University animal hospitals and private veterinary clinics.

Isopet^® for treating animals uses the same technology as RadioGel^™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO
MKorenko@RadioGel.com

FAQ

What is Vivos Inc.'s new partnership about?

Vivos Inc. has partnered with the Animal Hospital Surgical Center to establish an IsoPet regional therapy center specializing in cancer treatment for pets.

What will the IsoPet center focus on?

The IsoPet center will focus on treating cancerous tumor margins after surgery, potentially adding life extension for pets.

How does Vivos Inc.'s technology work?

Vivos Inc. uses yttrium-90 based injectable brachytherapy for targeted cancer treatment in animals and humans.

Where is the new IsoPet center located?

The new IsoPet center is located in East Meadow, New York, aimed at serving a large population area.

What is the expected outcome of the IsoPet center?

The center aims to provide specialized cancer treatment and generate additional revenue for Vivos Inc.